The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Decitabine for the treatment of acute myeloid leukemia (AML): Memorial Sloan-Kettering Cancer Center experience.
A. Ganetsky
No relevant relationships to disclose
N. G. Adel
No relevant relationships to disclose
M. G. Frattini
No relevant relationships to disclose
P. G. Maslak
No relevant relationships to disclose
M. L. Heaney
No relevant relationships to disclose
J. G. Jurcic
No relevant relationships to disclose
M. S. Tallman
No relevant relationships to disclose